Has Kali Jones received payments from drug or device companies?

Yes. Drug and device makers reported $744 in general payments to Kali Jones across 40 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kali Jones did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kali Jones come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kali Jones

Nurse Practitioner · Reading, PANPI 1306558101

Payments from drug & device makers

$744in general payments, 2019–2025

Across 40 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$229
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
Axsome Therapeutics, Inc.$98
Neurocrine Biosciences, Inc.$80
Alkermes, Inc.$76
Lundbeck LLC$22
plus $16 from 1 others

What the payments were for

Food & beverage$73298%
Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	15	$229
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	10	$224
Axsome Therapeutics, Inc.	5	$98
Neurocrine Biosciences, Inc.	4	$80
Alkermes, Inc.	4	$76
Lundbeck LLC	1	$22
E.r. Squibb & Sons, L.L.C.	1	$16

How this compares

$744 in reported general payments places this provider in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$5,590

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RexultiBrexpiprazole	11	$15,738
TrintellixVortioxetine Hydrobromide	17	$9,253
Bupropion XlBupropion Hcl	40	$1,329
Aripiprazole	35	$720
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	13	$685
Mirtazapine	62	$618
Doxepin Hcl	19	$607
Clonazepam	67	$563
Escitalopram Oxalate	34	$548
Trazodone Hcl	45	$397
Fluoxetine Hcl	31	$390
Hydroxyzine Hcl	35	$346
Quetiapine Fumarate	42	$319
Venlafaxine Hcl ErVenlafaxine Hcl	31	$257
Buspirone Hcl	23	$255

Paid to pharmacies, not to this prescriber.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other nurse practitioner in Reading